Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $30.50

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been given a consensus rating of "Buy" by the six research firms that are presently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $30.50.

A number of research analysts have issued reports on CPRX shares. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, August 9th. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday. Citigroup raised their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Finally, HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX traded down $0.12 during midday trading on Tuesday, reaching $23.33. 473,008 shares of the stock traded hands, compared to its average volume of 1,191,794. Catalyst Pharmaceuticals has a 12-month low of $12.43 and a 12-month high of $24.27. The business has a 50-day moving average of $20.81 and a two-hundred day moving average of $18.17. The stock has a market capitalization of $2.78 billion, a PE ratio of 19.87, a price-to-earnings-growth ratio of 3.82 and a beta of 0.75.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares of the company's stock, valued at $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares of the company's stock, valued at $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares in the company, valued at $13,738,773.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.00% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC grew its holdings in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 681 shares in the last quarter. nVerses Capital LLC acquired a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at $50,000. CWM LLC increased its stake in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 3,549 shares during the period. Meeder Asset Management Inc. acquired a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at $70,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at $153,000. Institutional investors and hedge funds own 79.22% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.